Researchers have found a way to make ordinary aluminum tubes float indefinitely, even when submerged for long periods or punched full of holes. By engineering the metal’s surface to repel water, the ...

Add Yahoo as a preferred source to see more of our stories on Google. This image provided by the FBI shows surveillance images at the home of Nancy Guthrie the night she went missing in Tucson, Ariz. ...

Another in the never ending supply of "War is Hell" films, this one is a time killer and nothing more. Thankfully Mitchum and Steiger are playing Americans, but no thanks to having Burton play a ...

This film is a sequel to Sam Peckinpah's CROSS OF IRON (1977) which I have not seen. The lead character, Sergeant Steiner of the Wehrmacht, is played by an aging Richard Burton who, despite only being ...

We hope you enjoyed that very brief warm up earlier this week because Syracuse will soon find itself locked back into a sub-zero freezer for a third consecutive weekend. The short burst of slightly ...

US-based Pacific Fusion has announced a major breakthrough in fusion research following four successful tests at Sandia National Laboratories’ Z Pulsed Power Facility. Here, researchers have delivered ...

The Breakthrough T1D San Francisco Gala returns for its 27th year, bringing the T1D community together for "A Magical Night Beneath the Cherry Blossoms" at the iconic San Francisco City Hall. This ...

A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...

Iran has vowed to hit back against any American military intervention - Copyright AFP STRINGER Iran has vowed to hit back against any American military intervention ...

US and Iranian officials are due this week to hold their first talks since Iran launched a deadly crackdown on protests, in a meeting likely to be crucial in determining if the US carries out renewed ...

Breakthrough therapy designation targets the post-CDK4/6 setting in PIK3CA-mutant HR+/HER2− advanced disease, where progression is common and therapeutic options remain constrained. Phase 1/2 ...